INCYTE REACHES AGREEMENT WITH FDA ON MF DRUG

    • MPNRF | May 3, 2020

    July 22, 2009

    The COMFORT-1 (COntrolled MyeloFibrosis Study with ORal Jak Treatment) trial will test the drug INCB18424 in patients with Primary Myelofibrosis, post-Polycythemia Vera Myelofibrosis or post-Essential Thrombocythemia Myelofibrosis. The Special Protocol Assessment (SPA) for the design of the trial is related to reduction in spleen size, a goal Incyte is confident they will meet.

    The trial, which will begin in August, has recruited 240 patients.

    Source:

    Reuters 

    Incyte press release